HKPD (Cellyan Biotechnology Co) Total Assets: $9.63 Mil (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKPD Cellyan Biotechnology Co Ltd HKPD
21 GF Score
Price $0.44
! 2 Warning Signs
View Full Analysis

What is Cellyan Biotechnology Co Total Assets?

Cellyan Biotechnology Co HKPD +0.40% 21 Total Assets is $9.63 Mil as of Sep. 2025. GuruFocus rates HKPD with a GF Score™ of 21/100. The stock has 2 warning signs investors should review.

Cellyan Biotechnology Co's Total Assets for the quarter that ended in Sep. 2025 was $9.63 Mil.

During the past 12 months, Cellyan Biotechnology Co's average Total Assets Growth Rate was -27.00% per year.

Total Assets is connected with ROA %. Cellyan Biotechnology Co's annualized ROA % for the quarter that ended in Sep. 2025 was 3.23%. Total Assets is also linked to Revenue through Asset Turnover. Cellyan Biotechnology Co's Asset Turnover for the quarter that ended in Sep. 2025 was 0.75.

Cellyan Biotechnology Co  (NAS:HKPD) Total Assets Explanation

Total Assets is connected with ROA %.

Cellyan Biotechnology Co's annualized ROA % for the quarter that ended in Sep. 2025 is

ROA %=Net Income (Q: Sep. 2025 )/( (Total Assets (Q: Mar. 2025 )+Total Assets (Q: Sep. 2025 ))/ count )
=0.308/( (9.417+9.634)/ 2 )
=0.308/9.5255
=3.23 %

Note: The Net Income data used here is two times the semi-annual (Sep. 2025) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Cellyan Biotechnology Co's Asset Turnover for the quarter that ended in Sep. 2025 is

Asset Turnover
=Revenue (Q: Sep. 2025 )/( (Total Assets (Q: Mar. 2025 )+Total Assets (Q: Sep. 2025 ))/ count )
=7.137/( (9.417+9.634)/ 2 )
=7.137/9.5255
=0.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Cellyan Biotechnology Co Total Assets Related Terms

Cellyan Biotechnology Co Total Assets Historical Data

* Premium members only.

The historical data trend for Cellyan Biotechnology Co's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cellyan Biotechnology Co Total Assets Chart

Cellyan Biotechnology Co Annual Data
Trend Mar23 Mar24 Mar25
Total Assets
3.41 8.67 9.42

Cellyan Biotechnology Co Semi-Annual Data
Mar23 Sep23 Mar24 Sep24 Mar25 Sep25
Total Assets Get a 7-Day Free Trial 0.00 8.67 10.16 9.42 9.63
HKPD
21GF Score
Cellyan Biotechnology Co Ltd HKPD
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cellyan Biotechnology Co Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Cellyan Biotechnology Co's Total Assets for the fiscal year that ended in Mar. 2025 is calculated as

Total Assets=Total Equity (A: Mar. 2025 )+Total Liabilities (A: Mar. 2025 )
=4.99+4.428
=9.42

Cellyan Biotechnology Co's Total Assets for the quarter that ended in Sep. 2025 is calculated as

Total Assets=Total Equity (Q: Sep. 2025 )+Total Liabilities (Q: Sep. 2025 )
=5.143+4.49
=9.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $9.63 Mil mean?
Cellyan Biotechnology Co (HKPD) has a Total Assets of $9.63 Mil as of Sep. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on Cellyan Biotechnology Co and its competitors.
Is Cellyan Biotechnology Co's Total Assets too high?
Cellyan Biotechnology Co's current Total Assets is $9.63 Mil. Overall, Cellyan Biotechnology Co has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Cellyan Biotechnology Co's Total Assets compare to COSM and SNYR?
Cellyan Biotechnology Co's Total Assets of $9.63 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Medical Distribution company?
A good Total Assets depends on the Medical Distribution industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Cellyan Biotechnology Co and its competitors. Cellyan Biotechnology Co's current Total Assets is $9.63 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cellyan Biotechnology Co stock overvalued right now?
Cellyan Biotechnology Co (HKPD) has a current Total Assets of $9.63 Mil. The current Total Assets is $9.63 Mil. Cellyan Biotechnology Co's overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Cellyan Biotechnology Co (HKPD), the current Total Assets is $9.63 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cellyan Biotechnology Co Business Description

Address 13 Ko Fai Road, Room B1, 5th Floor, Well Town Industrial Building, Yau Tong, Kowloon, Hong Kong, HKG
Cellyan Biotechnology Co Ltd formerly, Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market.
21GF Score

Get the complete analysis for HKPD

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.44
Price